iBio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from iBio, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 5,385% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.7 times its market value (net cash). Higher than 94% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 88% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Jun 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-71.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 78% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-42.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 69% of Healthcare companies in United States.
Cash Cushion Ratio
1.7× cashCash, after subtracting all debt, is 1.7 times its market value (net cash).
Higher than 94% of Healthcare companies in United States.
Tangible Assets Ratio
98%Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 85% of Healthcare companies in United States.
Tangible Net Worth Ratio
98%Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 88% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
iBio, Inc. made a loss over the last year. iBio, Inc. owes $0.14 for every $1 it owns. iBio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Jun 2026.
P/E ratio
LossiBio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.59The share price is 0.59 times iBio, Inc.'s book value per share, lower than 89% of Healthcare companies in United States.
Market cap
$50 MThe total market value of all of iBio, Inc.'s shares at today's price (share price × number of shares), smaller than 73% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$86 MWhat iBio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.33Net worth divided by the number of shares. The share price of $0.78 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-65.7%iBio, Inc. lost 65.7% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
Owes vs Owns
0.14×iBio, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Dividend yield
NoneiBio, Inc. does not currently pay a dividend.
Revenue growth
-75%Revenue fell 75% in the year to Jun 2026.
Profit growth
LossiBio, Inc. made a loss in each of the last two years.
Profit margin
-33044.0%iBio, Inc. lost $33044 for every $100 of revenue.
Interest cover
Not coverediBio, Inc.'s operating profit did not cover its interest costs in the year to Jun 2026.
Cash vs debt
Net cashiBio, Inc. held $86 M more cash than debt (net cash) at Jun 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For iBio, Inc.: $50 M ÷ $86 M (30 Jun 2026) = 0.6.
What is iBio, Inc.'s return on equity?
iBio, Inc. lost 65.7% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
How much does iBio, Inc. owe compared with what it owns?
iBio, Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Does iBio, Inc. pay a dividend?
No. iBio, Inc. does not currently pay a dividend.
Is iBio, Inc.'s revenue growing?
Revenue fell 75% in the year to Jun 2026.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.